Medicinovaincis A Publicly Traded Biopharmaceutical Company Focused On Acquiring And Developing Novelsmall Molecule Therapeutics For Treating Diseases With Unmet Medical Needsspecifically Focusing On The U Smarketthrough Strategic Alliances Primarily With Japanese Pharmaceutical Companiesmedicinova Holds Rights To A Diversified Portfolio Of Clinical And Preclinical Product Candidateseach Of Which Medicinova Believes Has A Well Characterized And Differentiated Therapeutic Profileattractive Commercial Potential And Patent Assets Having Claims Of Commercially Adequate Scopemedicinova S Pipeline Includes Clinical Stage Compounds For The Treatment Of Acute Exacerbations Of Asthma And Copdprogressive Multiple Sclerosismethamphetamine Addictionneuropathic Painasthmainterstitial Cystitisand Solid Tumor Cancersmedicinova S Current Strategy Is To Focus On Mn 166Ibudilastfor Neurological Disordersmn 221 For The Treatment Of Acute Exacerbations Of Asthmaand Mn 001 For Nashmedicinova May Pursue Development Independently Or Establish A Strategic Collaboration To Support Further Development Of Its Programsmedicinova Will Seek To Monetize Its Other Product Candidates At Key Value Inflection Pointsmedicinova S Executive Management Team Has Extensive Global Developmentregulatorycommercial And Financial Experienceand Manages Its International Clinical And Manufacturing Operations Through Efficient And Cost Effective Utilization Of Contract Research Organizationsmedicinova Is Headquartered In La Jollacalifornia
